DE3854328D1 - Nukleinsäuren und methoden für die synthese von neuen fusionspolypeptiden mit einem phospholipidankergebiet. - Google Patents

Nukleinsäuren und methoden für die synthese von neuen fusionspolypeptiden mit einem phospholipidankergebiet.

Info

Publication number
DE3854328D1
DE3854328D1 DE3854328T DE3854328T DE3854328D1 DE 3854328 D1 DE3854328 D1 DE 3854328D1 DE 3854328 T DE3854328 T DE 3854328T DE 3854328 T DE3854328 T DE 3854328T DE 3854328 D1 DE3854328 D1 DE 3854328D1
Authority
DE
Germany
Prior art keywords
synthesis
methods
nucleic acids
fusion polypeptides
anchor area
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3854328T
Other languages
English (en)
Other versions
DE3854328T2 (de
Inventor
Ingrid Caras
Victor Nussenzweig
Michael A Davitz
David W Martin Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
New York University NYU
Original Assignee
Genentech Inc
New York University NYU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, New York University NYU filed Critical Genentech Inc
Publication of DE3854328D1 publication Critical patent/DE3854328D1/de
Application granted granted Critical
Publication of DE3854328T2 publication Critical patent/DE3854328T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • C07K2319/912—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation containing a GPI (phosphatidyl-inositol glycane) anchor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Nanotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
DE3854328T 1987-08-06 1988-08-03 Nukleinsäuren und methoden für die synthese von neuen fusionspolypeptiden mit einem phospholipidankergebiet. Expired - Lifetime DE3854328T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/083,757 US5109113A (en) 1986-05-02 1987-08-06 Membrane anchor fusion polypeptides
PCT/US1988/002648 WO1989001041A1 (en) 1987-08-06 1988-08-03 Nucleic acid and methods for the synthesis of novel fusion polypeptides with a phospholipid anchor domain

Publications (2)

Publication Number Publication Date
DE3854328D1 true DE3854328D1 (de) 1995-09-21
DE3854328T2 DE3854328T2 (de) 1996-03-28

Family

ID=22180508

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3854328T Expired - Lifetime DE3854328T2 (de) 1987-08-06 1988-08-03 Nukleinsäuren und methoden für die synthese von neuen fusionspolypeptiden mit einem phospholipidankergebiet.

Country Status (8)

Country Link
US (1) US5109113A (de)
EP (1) EP0371999B1 (de)
JP (1) JP2935709B2 (de)
AU (1) AU629517B2 (de)
CA (1) CA1341485C (de)
DE (1) DE3854328T2 (de)
IL (1) IL87366A (de)
WO (1) WO1989001041A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291662B1 (en) 1984-12-05 2001-09-18 Amgen Inc. Recombinant methods for production of serine protease inhibitors and DNA sequences
US5871956A (en) * 1984-12-06 1999-02-16 Amgen Inc. Recombinant methods for production of serine inhibitors and DNA sequences useful for same
US6132990A (en) * 1984-12-06 2000-10-17 Amgen Boulder Inc. Recombinant methods for production of serine protease inhibitors and DNA sequences useful for same
US5900400A (en) * 1984-12-06 1999-05-04 Amgen Inc. Serine protease inhibitor analogs
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
US5223394A (en) * 1989-04-10 1993-06-29 Biogen, Inc. Recombinant dna molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence
JP2828148B2 (ja) * 1989-04-21 1998-11-25 山之内製薬株式会社 ヒトｍａｃｉｆ活性蛋白遺伝子、該遺伝子を結合した発現ベクター、形質転換細胞及びヒトｍａｃｉｆ活性蛋白
US5573940A (en) * 1989-06-12 1996-11-12 Oklahoma Medical Research Foundation Cells expressing high levels of CD59
EP0406857B1 (de) * 1989-07-07 1995-05-24 Takeda Chemical Industries, Ltd. Proteine und deren Herstellung
US5514787A (en) * 1989-07-21 1996-05-07 Washington University DNA sequences encoding human membrane cofactor protein (MCP)
AU651068B2 (en) * 1989-07-21 1994-07-14 Washington University Recombinantly produced human membrane cofactor protein (MCP)
DE69005572T2 (de) * 1989-09-08 1994-04-07 Takeda Chemical Industries Ltd Fusionsproteine und Herstellung davon.
US6482404B1 (en) 1989-10-12 2002-11-19 David James White Transplantation of tissue comprising a DNA sequence encoding a homologous complement restriction factor
RO109863B1 (ro) 1989-10-12 1995-06-30 Imutran Ltd Gena care codifica cel putin un factor de restrictie complementar, animal transgenic si metode de transplantare a tesuturilor sau organelor animale
US20010018051A1 (en) * 1990-04-09 2001-08-30 White David James Graham Inhibition of allograft and concordant xenograft rejection
US5241053A (en) * 1990-09-05 1993-08-31 Takeda Chemical Industries, Ltd. Fused proteins comprising glycoprotein gD of HSV-1 and LTB
EP0477739A3 (en) * 1990-09-27 1992-12-09 F. Hoffmann-La Roche Ag Glycosyl-phosphatidylinositol-specific phospholipase d
US20050209121A1 (en) * 1990-12-05 2005-09-22 Novozymes A/S Proteins with changed epitopes and methods for the production thereof
US6967080B1 (en) * 1990-12-05 2005-11-22 Novozymes A/S Proteins with changed epitopes and methods for the production thereof
EP0512733A2 (de) * 1991-05-03 1992-11-11 Washington University Modifizierter Komplementsystemregler
US5632986A (en) * 1991-05-09 1997-05-27 The University Of Washington Phospholipid-targeted thrombolytic agents
US6869925B1 (en) * 1992-09-09 2005-03-22 Amgen Inc. Inhibition of retrovirus infection
BR9400600A (pt) * 1994-02-17 1995-10-24 Finep Financiadora De Estudos Processos para produção de uma protéina recombinante e/ou de glicosilfosfatidilinositol (GPI) em células de microorganismos eucariontes e para a obtenção de leveduras de S. cerevisae; célula de levedura sequência de nucleotídios; meio de cultura; medicamento ou vacina; e produto dos ditos processos
US6017880A (en) * 1994-03-09 2000-01-25 Amgen Inc. Inhibition of retrovirus infection
JP2000504330A (ja) * 1996-01-29 2000-04-11 ジョージタウン・ユニヴァーシティ 発現された組換えタンパク質から得られる応答の増幅
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
DE69833545T2 (de) * 1997-03-26 2006-12-14 Imperial College Innovations Ltd. In der zellmembran verankertes antikoagulant-fusionsprotein
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
GB9910077D0 (en) 1999-05-01 1999-06-30 Univ Manchester Chemical compounds
CN100421730C (zh) * 2002-07-10 2008-10-01 英特威国际有限公司 免疫原性组合物
CN1918299B (zh) * 2004-02-09 2013-04-17 西纳门公司 用于生产拴系蛋白的方法
DOP2007000021A (es) * 2006-02-02 2007-08-31 Rinat Neuroscience Corp Procedimientos para tratar pérdida de peso no deseada o trastornos alimentarios administrando un agonista de trkb
EP1988920A1 (de) * 2006-02-02 2008-11-12 Rinat Neuroscience Corp. Verfahren zur behandlung von fettsucht durch verabreichung eines trkb-antagonisten
EP2066697A2 (de) * 2006-09-26 2009-06-10 Massachusetts Institute of Technology Modifizierte selbstanordnende peptide
EP2112164A1 (de) * 2008-04-23 2009-10-28 Institut Pasteur Of Shanghai Antivirale Peptide mit Lipidbindungssignalen und Verfahren zu ihrer Verwendung
EP2096121A1 (de) * 2008-02-29 2009-09-02 Institut Pasteur Of Shanghai Antivirale Peptide mit Lipidbindungssignalen und Verfahren zu ihrer Verwendung

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4480041A (en) * 1982-07-09 1984-10-30 Collaborative Research, Inc. Use of phosphotriester intermediates for preparation of functionalized liposomes
IL82390A0 (en) * 1986-05-02 1987-10-30 Genentech Inc Nucleic acid and methods for the synthesis of novel daf compositions

Also Published As

Publication number Publication date
IL87366A0 (en) 1989-01-31
US5109113A (en) 1992-04-28
CA1341485C (en) 2005-07-12
AU629517B2 (en) 1992-10-08
JPH02504467A (ja) 1990-12-20
WO1989001041A1 (en) 1989-02-09
EP0371999A1 (de) 1990-06-13
AU2308788A (en) 1989-03-01
JP2935709B2 (ja) 1999-08-16
DE3854328T2 (de) 1996-03-28
EP0371999B1 (de) 1995-08-16
IL87366A (en) 1993-08-18

Similar Documents

Publication Publication Date Title
DE3854328T2 (de) Nukleinsäuren und methoden für die synthese von neuen fusionspolypeptiden mit einem phospholipidankergebiet.
DE3485723D1 (de) Verfahren und signalsequenz fuer die extrazellulare herstellung von proteinmaterial.
DE68908447D1 (de) Verfahren zur herstellung von gelen aus mineralischen tonen und polymeren, die auf reversible weise wasser aufnehmen koennen.
DE3677044D1 (de) Verfahren zur herstellung von emulsionen und die so erhaltenen emulsionen.
DE3669658D1 (de) Antithrombogenes, nichtcalcifizierendes material und ein verfahren zur herstellung von gegenstaenden fuer medizinische zwecke.
FI881657A0 (fi) Menetelmä helmien valmistamiseksi tarkoituksena tuottaa hallitusti vapauttavia tuotteita
DE3486025T2 (de) Interpolymere von aethylen und ungesaettigten saeuren.
IT8620901A0 (it) Procedimento di fabbricazione distrutture di rivoluzione tridimensionali mediante cucitura di strati piani di materiale fibroso e materiale utilizzato perl'attuazione del procedimento.
DE68905553T2 (de) Feste base, verfahren fuer ihre herstellung und ihre verwendung fuer die bereitung von olefinen.
ATA122485A (de) Verfahren zur herstellung von neuen 1,4-dihydro-4-oxonaphthyridin-derivaten und deren salzen
DE3863195D1 (de) Feste base, verfahren zu deren herstellung und ihre anwendung fuer die herstellung von olefinen mit innerer doppelbindung.
DE69022337T2 (de) 2-Stufenverfahren zur Synthese von Kohlenwasserstoffen.
DE3675078D1 (de) Verfahren zur synthese von hexafluorbutadien und von hoeheren perfluorierten dienen.
ES554180A0 (es) Procedimiento para la produccion de material compuesto a base de matriz polimerica
DE3869317D1 (de) Verfahren zur programmierung von speicherzellen und schaltkreis fuer die durchfuehrung dieses verfahrens.
DE68910192D1 (de) Verfahren zur Dehydrierung von Kohlenwasserstoffen die aus einer Kombination von isothermischen und adiabatischen Stufen zusammengesetzt sind.
DE3883797T2 (de) Elektro-Schmelzschweissen von thermoplastischen Materialien.
DE69005392T2 (de) Auftragskopf für die Auflegung von Verbundwerkstoffbänder.
DE3685919D1 (de) Ultraschallpruefung von werkstoffen.
DE3676049D1 (de) Verfahren zur herstellung von thermoplastischen massen.
AT360184B (de) Verfahren zur herstellung von neuen pentapep- tiden, deren c-terminalen estern und amiden sowie von deren salzen
DE3850172T2 (de) Zusammengesetztes Material für die Innenausstattung von Fahrzeugen.
ATA171986A (de) Verfahren zur herstellung von neuen, in 3-stellung substituierten propenylaminothiazolylcephalosporansaeuren und deren estern
EP0149241A3 (en) Dna base sequence containing regions involved in the production and secretion of a protein, recombinant dna including the whole or a part of the dna base sequence, and method of producing proteins by use of the recombinant dna
PT90976A (pt) Processo para a preparacao de proteinas e de acidos nucleicos

Legal Events

Date Code Title Description
8364 No opposition during term of opposition